India's Covaxin shot 78% effective against coronavirus, say developers
- Country:
- India
India's only domestically developed COVID-19 vaccine, Covaxin, has been found to be 78% effective in a second analysis of clinical trials done around the country, its makers said https://www.bharatbiotech.com/images/press/covaxin-phase3-clinical-trials-interim-results.pdf on Wednesday.
"I am very pleased to state that Covaxin ... has shown the efficacy of 78% in the second interim analysis," said Balram Bhargava, the chief of the state-run Indian Council of Medical Research that has created the vaccine with Bharat Biotech.
The first analysis released in March had shown an efficacy rate of 81%.
ALSO READ
-
Cleaner Kitchens, Polluted Skies: Hidden Health Cost of India’s Electricity Boom
-
Japan-Backed ILO Projects Help 23,000 Workers Gain Rights and Fight Child Labour
-
India's Delicate Balancing Act: Navigating Energy Security Amid Middle Eastern Tensions
-
India Gears Up for Glory: Asian Games 2026 Preview
-
India Defends Energy Policy Amidst Rising Tariff Threats from U.S.
Google News